News Release Details
Verrica Announces Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Annual Meeting
VP-102 is a proprietary topical drug-device combination therapy in development for the treatment of molluscum contagiosum, a highly contagious, primarily pediatric, viral skin infection that affects an estimated six million people in
The presentation, “CAMP-1 (Cantharidin Application in Molluscum Patients) and CAMP-2: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Studies Investigating VP-102, a Drug-Device Combination Containing a Novel Topical Formulation of Cantharidin, for the Treatment of Molluscum Contagiosum,” will take place during the
The CAMP-1 and CAMP-2 studies enrolled 528 patients in total and were conducted at 31 centers in the
Verrica will also present an abstract from its Phase 2 Innovate study in an online e-poster titled “Innovate: A Phase 2 Study Investigating VP-102, a Drug-Device Combination Containing a Novel Topical Formulation of Cantharidin, for the Treatment of Molluscum Contagiosum.”
About VP-102
Verrica is currently advancing its lead product VP-102, a proprietary topical drug-device combination therapy containing a topical solution of 0.7% cantharidin in a novel, single-use applicator, for the treatment of molluscum contagiosum, verruca vulgaris (common warts), and external genital warts.
About Molluscum Contagiosum
Molluscum contagiosum, or molluscum, is a highly contagious, primarily pediatric, viral skin infection affecting an estimated six million people in
About
Verrica is a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs. Verrica is headquartered in
IR Contacts:
Chief Financial Officer
484.453.3300 ext. 103
info@verrica.com
Westwicke Partners
415.513.1284
Patti.bank@westwicke.com
Media Contact:
Sam Brown Inc.
312.961.2502
mikebeyer@sambrown.com
Source: Verrica Pharmaceuticals Inc.